Fundz

Onl Therapeutics Closes 2Nd Tranche Of $46.9 Million Series B Financing Upon Achieving Onl1204 Development Milestones

PRIVATEJan 13, 2022

Amount Raised

$46.9 Million

Round Type

Series B

Ann ArborBiotechnologyHealth CareBiopharma

Description

ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, today announced it has closed on its second tranche of the Company’s Series B financing. The total proceeds raised in the Series B was $46.9 million.

Who else raised in Biopharma and Biotechnology around the same time

Companies in the same sectors as ONL Therapeutics that raised within 45 days of this round, from Fundz verified event records.

  • Cumulus Oncology raised $5.4M on February 22, 2022.
  • Arbutus raised $15M on December 30, 2021.
  • AnHeart Therapeutics raised $61M (Series B) on December 14, 2021.
  • AEON Biopharma raised $30M on December 8, 2021.
  • Amarna Therapeutics raised $5.4M (Funding Round) on December 1, 2021.
  • Kernal Biologics raised $20M on February 25, 2022.

Who to call at ONL Therapeutics, and when

A new round usually means ONL Therapeutics is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day ONL Therapeutics raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at ONL Therapeutics, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at ONL Therapeutics. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

ONL Therapeutics

Location

524 S. Main St

Ann Arbor, Michigan, United States

About

ONL Therapeutics (ONL) is a clinical-stage biopharmaceutical company committed to developing first-in-class therapeutics to protect and improve the vision of patients with retinal disease. By advancing a breakthrough technology designed to protect key retinal cells from Fas-mediated cell death, ONL is pioneering a new approach to preserving vision.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment ONL Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

1 contact
Verified contactsDavid E., Executive Officer, Director hiddenSee plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for ONL Therapeutics's next move

See what Strategic adds

Funding Insights

What this usually means
Timeline to next round
Series B companies typically work for 15-20 months before raising new capital
Growth expectations
Series B companies are expected to scale rapidly and expand market reach

ONL Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.